echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The United States approves the first Alzheimer's disease drug in the past 20 years at an annual cost of 56,000 US dollars

    The United States approves the first Alzheimer's disease drug in the past 20 years at an annual cost of 56,000 US dollars

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 7, local time, the U.
    S.
    Food and Drug Administration (FDA) issued a statement on its official website stating that it approved the Aduhelm (aducanumab) developed by the pharmaceutical company Biogen to treat patients with Alzheimer’s disease.
    It is the first new treatment approved for Alzheimer's disease since 2003
    .

    According to reports, the company and its Japanese partner Eisai Co.
    , Ltd.
    stated in an announcement that the annual treatment cost of Adunazumab is $56,000
    .


    Affected by this news, Biogen's stock price rose 58%


    According to the timeline, Biogen completed the submission of aducanumab listing application materials on July 8, 2020, and was officially accepted by the FDA on August 7, 2020, and obtained priority review qualifications.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.